4,6-Dichloro-2-Methylpyrimidine CAS 1780-26-3 Pite ≥99.5% (GC) faktori cho vann

Deskripsyon kout:

Non chimik: 4,6-Dichloro-2-Methylpyrimidine

CAS: 1780-26-3

Pite: ≥99.5% (GC)

Aparans: White oswa Off-White Crystalline Powder

Segondè Kalite, Pwodiksyon Komèsyal

Entèmedyè nan Dasatinib / Moxonidine

E-Mail: alvin@ruifuchem.com

Voye imèl ba nou

Pwodwi detay

Pwodwi ki gen rapò

Tags pwodwi

Deskripsyon:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com

Pwopriyete chimik:

Non Chimik	4,6-Dichloro-2-Methylpyrimidine
Sinonim	2-Methyl-4,6-Dichloropyrimidine;2,4-Dichloro-6-Methylpyrimidine
Nimewo CAS	1780-26-3
Nimewo CAT	RF-PI687
Estati Stock	Nan Stock, Pwodiksyon Echèl Jiska Tòn
Fòmil molekilè	C5H4Cl2N2
Pwa molekilè	163.00
Pwen k ap fonn	41.5 ~ 45.5 ℃ (lit.)
Solibilite (Soluble nan)	Methanol
Mak	Ruifu Chimik

Espesifikasyon:

Atik	Espesifikasyon
Aparans	Poud kristalin blan oswa blan
Pite / Metòd analiz	≥99.5% (GC)
Pèt sou siye	≤0.50%
Rezid sou ignisyon	≤0.20%
Single enpurte	≤0.50%
Enpurte total	≤0.50%
Tès Creole	Enterprise Standard
Itilizasyon	Famasetik Entèmedyè;Dasatinib/Moxonidine Entèmedyè

4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) Wout pwosesis

Pake & Depo:

Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an

Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite

Avantaj:

FAQ:

Aplikasyon:

4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) yo itilize nan sentèz entèmedyè pharmaceutique ak APIs.Pwodwi Preparasyon: Moxonidine (CAS: 75438-57-2);Dasatinib (CAS: 302962-49-8);Dasatinib monoidrat (CAS: 863127-77-9);4-Chloro-2,6-Dimethylpyrimidine (CAS: 4472-45-1);4-Amino-6-Chloro-2-Methylpyrimidine (CAS: 1749-68-4).Moxonidine se yon nouvo kalite dwòg antihypertansive, souvan itilize nan tretman tansyon wo esansyèl.Konpare ak pi gran antihypertensives santral ki aji, Moxonidine mare ak pi gwo afinite ak imidazoline I1-reseptè a pase ak α2-reseptè a.Dasatinib se yon inibitè kinaz onkogenik oral ki pisan, ki ka bloke siyal akselerasyon replikasyon selil kansè yo, nan mwa me 2009, Administrasyon Manje ak Medikaman Ameriken an (FDA) te apwouve fòmèlman vant dasatinib, li te klinikman itilize pou tretman divès kalite kwonik. lesemi myeloid (CML), ki gen ladan tretman lesemi myeloid kwonik ki rezistan oswa entoleran nan pwogram tretman yo ki gen ladan imatinib mesylate., Philadelphia kwomozòm-pozitif lesemi lenfoblastik egi (Ph + ALL) ak tretman pasyan ki gen timè solid.